Figure 2From: Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexateThe prevalence of abnormal liver stiffness measurement (LSM) values among patients with rheumatoid arthritis receiving methotrexate with a cumulative dose of leflunomide over 19,170 mg. Abnormal LSM values were more frequently identified in patients with cumulative doses of leflunomide ≥ 19,170 mg than in those with cumulative doses of leflunomide < 19,170 mg (69.2% (9/13 patients) vs. 15.0% (6/40 patients), P < 0.001).Back to article page